LGALS12 and atopic eczema: Given that both galectin-12 knockdown and PPARγ inhibition (GW9662) lead to reduced CCL26 expression and improved atopic dermatitis symptoms, as described above, galectin-12 might sustain Th2 immune responses by reinforcing PPARγ activation in sebocytes [69].